Zacks Investment Research upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a research report released on Thursday. They currently have $46.00 target price on the stock.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Several other analysts have also recently commented on CTLT. BidaskClub cut shares of Catalent from a buy rating to a hold rating in a research report on Tuesday, November 14th. ValuEngine cut shares of Catalent from a buy rating to a hold rating in a research report on Friday, December 1st. Royal Bank of Canada started coverage on shares of Catalent in a research report on Wednesday, December 13th. They set an outperform rating and a $46.00 target price for the company. First Analysis initiated coverage on shares of Catalent in a research report on Friday, January 5th. They set an equal weight rating for the company. Finally, Goldman Sachs Group initiated coverage on shares of Catalent in a research report on Wednesday, January 24th. They issued a buy rating and a $50.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $45.40.
Catalent (NYSE:CTLT) last issued its earnings results on Monday, February 5th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to analysts’ expectations of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The business’s revenue for the quarter was up 25.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS. analysts expect that Catalent will post 1.53 earnings per share for the current fiscal year.
In related news, insider John R. Chiminski sold 181,458 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.70% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Champlain Investment Partners LLC boosted its stake in Catalent by 10.9% in the 4th quarter. Champlain Investment Partners LLC now owns 3,043,715 shares of the company’s stock worth $125,036,000 after purchasing an additional 298,015 shares during the period. American Century Companies Inc. boosted its stake in Catalent by 755.3% in the 4th quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock worth $108,108,000 after purchasing an additional 2,323,971 shares during the period. Earnest Partners LLC boosted its stake in Catalent by 0.5% in the 3rd quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock worth $102,601,000 after purchasing an additional 12,652 shares during the period. Macquarie Group Ltd. boosted its stake in Catalent by 15.8% in the 3rd quarter. Macquarie Group Ltd. now owns 2,069,323 shares of the company’s stock worth $82,607,000 after purchasing an additional 282,559 shares during the period. Finally, Brown Advisory Inc. boosted its stake in Catalent by 4.3% in the 4th quarter. Brown Advisory Inc. now owns 2,031,955 shares of the company’s stock worth $83,473,000 after purchasing an additional 83,441 shares during the period. 99.03% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2018/03/12/catalent-ctlt-lifted-to-buy-at-zacks-investment-research.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.